Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry...(Will try to post again):
Ann
Here's the latest 8-K:
http://investorshub.advfn.com/boards/board.asp?board_id=113
Ann
Ninja:
Link worked - got it - TY.
Ann
ninja:
"DNAG symbol is changing to DNAGE."
Can you provide a link?
Take care,
Ann
Hanging in there til we know something for sure. Doesn't the 10K come out in the middle of the month?
Ann
Johnnyfiber:
Wouldn't DNAP have already known this, since this is a '07 filing, before inking a deal with Nanobac?
Just curious about your thoughts.
Take care,
Ann
Here's an overview of Nanobac you can scout n your spare time - lol
http://investing.businessweek.com/research/stocks/people/people.asp?symbol=NNBP.OB
Ann
NNBP: Research Collaboration Agreement with BioChemics
03/25/2008 09:57:57 AM EDT
Knobias
Ridgeland, MS, MAR 25, 2008 (EventX/Knobias.com via COMTEX) -- By Fain Hughes, fhughes@knobias.com
Nanobac Pharmaceuticals, Inc. (NNBP) announced a research collaboration agreement with BioChemics Inc. (BCI) to utilize BCI's patented drug delivery technology (VALE(R)) for the transdermal (topical) delivery of Nanobac compounds for the treatment of prostatitis. Terms of the deal include upfront payments already made, future payments, R&D support as well as milestones for success for BCI.
Ann
DNA Testing inks agreement w/DNAP:
http://money.aol.com/news/articles/qp/pr/_a/dna-testing-systems-inks-agreement-with/rfid80350689
Ann
DNAP page:
http://www.manta.com/coms2/dnbcompany_gsfc31
Ann
DNAPrint Genomis, Inc. Info:
http://reports.manta.com/coms2/description/8s38nc-110110008-0319
Ann
Agreement dated 3/11/08:
http://money.aol.com/news/articles/qp/pr/_a/dna-testing-systems-inks-agreement-with/rfid80350689
Ann
pt:
It looks that way, since I have not seen it before. I have not surfed the DNAP site for a while.
Take care,
Ann
From DNAP website:
http://dnaprint.com/welcome/productsandservices/otherproducts/others/
Ann
DNA Testing Systems Inks Agreement with DNAPrint Genomics
PR Newswire
Posted: 2008-03-11 08:15:05
SCOTTSDALE , Ariz., March 11 /PRNewswire-FirstCall/ -- DNA Testing Systems, previously of Santa Fe , N.M., and formerly named DNA Consulting, has signed an agreement to sell DNAPrint Genomics' line of biogeographical ancestry tests and has moved its offices to Scottsdale , Ariz.
DNAPrint Genomics of Sarasota , Fla., was one of the first DNA testing companies to be formed in an industry now estimated to be worth over $150 million in consumer sales. It was launched in 1997 to commercialize the biogeographical, and proprietary, genetic markers developed from the work of Mark Shriver , a biogenetics professor at Pennsylvania State University.
DNA Testing was a spin-off from the research of founder Donald N. Yates into the Jewish and American Indian genetics of a rare Appalachian ethnic group called Melungeons, a family background to which he belongs. "I had to start my own company to understand my own unusual DNA test results," Yates said. "And then I was doing so many consultations for Melungeon cousins that I decided to commercialize my sideline and get paid for what I was doing."
Yates moved his business from Savannah, Ga., where he was a professor, to Santa Fe , N.M., in 2004 and has now settled in Scottsdale , where he hopes one day to retire. The company uses genomics laboratories in Salt Lake City , Utah; Richmond , Calif., and Sarasota , Fla.
DNA Testing sells DNAPrint(R) tests through a large web presence, marketing them as Whole DNA, a test that estimates percentages of American Indian and other admixture; EurasianDNA, which divides a customer's DNA into four regions of Eurasia, and EuroDNA 2.0, the newest ancestry test from DNAPrint. EuroDNA 2.0 uses discoveries in genetic markers and human migration to determine an individual's proportion of ancestry in five parts of Europe , including the Iberian Peninsula.
According to Yates, "We are finding that many people who think they are exclusively English, Irish and Scottish have a large element of Spanish and Portuguese ancestry they did not suspect." One reason, he said, was that the British Isles were settled chiefly by a people very much like the Basques after the last Ice Age.
Of the handful of DNA testing companies in the United States , DNA Testing is the only one that specializes in customized and personalized reports. "We're rather boutique-like in our approach," said Yates, "and probably want to keep it that way." In addition to biogeographical DNA tests, the company also sells traditional paternity, Y chromosome (male) and mitochondrial (female-passed DNA) tests.
Ann
Dr. Maniscalco of Nanobac:
Dr. Maniscalco has been repeatedly voted by physician peers as one of the "Best Doctors in America." He founded St. Joseph's Hospital Heart Institute in Tampa and is head of the internationally recognized Heartbeat International which donates life saving pacemakers in lesser developed countries. He was principle investigator in a study on a novel therapy for atherosclerosis.
Dr. Hector Gomez, M.D. PhD, will be special advisor to Dr. Maniscalco on drug and diagnostics development. He is a former Merck and Novartis research executive with extensive experience bringing therapies to market in FDA and European regulatory environments, and in supervising clinical trial work in other countries. He has successfully brought biotech companies public and currently heads an R&D company near Tampa.
"Dr. Maniscalco's and Dr. Gomez' combination of clinical treatment, medical innovation and drug development experience adds a needed dimension to the quest for an effective treatment for stone forming diseases," said John Stanton, CEO and Chairman. "This will enhance our focus on proving the effectiveness of drug combinations in ways that will meet new FDA drug and diagnostics standards."
Ann
Nanobac & Nanotechnology:
“Nanobac is deep into landmark medical research that we believe will redefine the way we view disease and change the way physicians approach the treatment of illnesses,” said Nanobac Co-Chairman Dr. Benedict Maniscalco. “We believe utilizing the experienced professionals at The Aker Partners will not only increase the visibility of our work in the field of medical nanotechnology, but also enhance the viability of our company.”
Nanotechnology is the realm of discovering and exploiting the special characteristics of materials at the atomic scale. A nanoparticle is generally considered to be anything less than 100 nanometers, or 100 billionths of a meter. If a one-meter ruler could be stretched from New York City to Los Angeles, a nanometer on that ruler would still be only the size of an aspirin.
The specialized type of medical nanotechnology being pursued by Nanobac aims to combat disease on that “nano” scale by detecting calcifying nanoparticles that straddle the 100 nanometer size line, ranging in diameter from 75 nm to more than 500 nm. Researchers believe these CNPs are the basic cause of a multitude of illnesses.
Ann
DNAPrint Technical Information:
http://reports.manta.com/coms2/description/8s38nc-110110008-0319
Ann
An overview of Nanobac:
http://www.manta.com/coms2/dnbcompany_gycbyy
Ann
"An order of 600,000 ANCESTRYbyDNA tests will be quite a boon for DNAPrint Genomics, which has been actively seeking markets other than traditional genetic genealogy consumers. And it is possible that this initiative will create a demand for this type of data in many more studies of biological samples."
Ann
600,000 Genealogy Tests for DNAP:
http://www.thegeneticgenealogist.com/2007/10/18/dnaprint-and-bioserve-600000-genetic-genealogy-tests/
Ann
Special Report on Human Genomics:
Personal Genomics Companies Selling Genetic Testing to the Public
Company Product(s) and
Cost
The Fate of your DNA Sample
DNA Print Genomics, Inc.
http://www.dnaprint.com
(Florida, USA)
Subsidiaries: Biofrontera AG, a
German specialty pharma co. and
Trace Genetics, genetic identity
DNA analysis
AncestrybyDNA
$210-$650
Also sells
Pharmacogenomic,
Forensics products (i.e,
DNAWitness) but not
DTC)
Legal agreement is not available on web site, but
is included with DNA sample kit. “The test results
will be returned to you by U.S. standard mail.
Your information will be kept confidential…
however they may be subpoenaed by court
order, which DNAPrint® shall be required by law
to turn over the results of the tests to the proper
authorities.”
http://www.ancestrybydna.com/welcome/consentform/
(28 Feb. 2008)
Ann
6 MORE DAYS!
For the filings, Jever?
Ann
DoggyDNA - '07...
http://www.eyeondna.com/2007/08/16/eye-on-doggie-dna/
Ann
From Nanobac board:
Posted by: nanopatent
In reply to: None Date:2/1/2008 12:36:29 PM
Post #of 423
DNAPrint Genomics patent position
Results of Search in US Patent Collection db for:
AN/"DNAPrint Genomics": 2 patents.
Hits 1 through 2 out of 2
PAT. NO.
Title
1
7,110,885
Efficient methods and apparatus for high-throughput processing of gene sequence data
2
7,107,155
Methods for the identification of genetic features for complex genetics classifiers
http://tinyurl.com/22t8nb
Results of Search in PGPUB (Published Applications) (Published Applications) Production Database for:
AN/"DNAPrint Genomics": 1 applications.
Hits 1 through 1 out of 1
PUB. APP. NO.
Title
1
20070020651
Compositions and methods for the inference of pigmentation traits
http://tinyurl.com/22k4ql
RESULT LIST
14 results found in the Worldwide database for:
DNAPrint Genomics as the applicant
http://tinyurl.com/2eaovq
Looks good, promising and most of all - tremendously PROFITABLE.
Agreed?!!!!!
Time to load the boat - remember Mayo, NASA, China, Finland, Canada (anybody I forgot?).
Ann
That was posted on Genetic Geneologist - not Genomeweb.
Ann
GenomeNews - 2/4/08:
DNAPrint Genomics to be Acquired by Nanobac Pharmaceuticals
GenomeWeb Daily News announced on Friday that DNAPrint Genomics is being purchased by Nanobac Pharmaceuticals (I’ve written about DNAPrint here and here, including about their Doggie DNAPrint product). Here is the press release from Nanobac.
DNAPrint had a big year in 2007 with a number of partnerships and new products, and many people have forgotten or were unaware that the autosomal genetic genealogical tests offered by DNAPrint’s AncestrybyDNA are just a small part of the company’s business. From the Nanobac press release:
“DNAG’s primary objective has been, and Nanobac’s primary objective will be, to develop progressive theranostics drugs, which combine extensively modeled drugs with genomics-derived intelligence to create more economical and powerful drug/test combination products with superior performance parameters. DNAG’s flagship product, PT-401, is expected to result in more effective treatment of anemia, and its Protectin(TM) (CD-59) diagnostic test is expected to allow patients and their physicians to more effectively manage the risks and treatment decisions for diabetes. DNAG supports its clinical programs, in part, through the sale of consumer genetics tests genotyping services on a contractual basis.”
Ann
Stockhldr:
In your reply that "personalized medicine is dead..."
"From the Nanobac acquisition PR..."
DNAG's primary objective has been, and Nanobac's primary objective will be, to develop progressive theranostics drugs, which combine extensively modeled drugs with genomics-derived intelligence to create more economical and powerful drug/test combination products with superior performance parameters.
We'll see...& we will hope the "deal" goes through!
Ann
Altar:
This is obviously a situation that we can't be apprised of yet as we are now playing a waiting game of whether or not Nanobac comes through. Good or bad news will be the inevitable answer probably soon. The rest is guesswork on our part as of now.
Like you say, Alter...pray real hard!
Take care,
Ann
Sharing an e-mail I received from Louise at DNAP:
"Are we "done" as investors in DNAP or is there still "hope" for us with Nanobac?"
Hello Ann, as you know, we have been working diligently on financing but at this point, there is no infomation to announce to everyone. As soon as we have something to share, we will let you know.
thank you for your continued patience.
Louise
Investor Relations
DNAPrint genomics, Inc.
V 941-366-3400
dnap@dnaprint.com
Ann
Nanobac still in acquiring mode?
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=5771014&Type=HTML
Ann
Sorry, just realized it is dated.
Ann
David:
Hopefully that won't occur before agreement is completed.
Take care & thank you,
Ann
David:
What happens if the pps goes to 0 while we are awaiting the news?
First-time intestment. Just wondering.
Ann
Thank you, David.
We should know by the end of this month or sooner?
Take care,
Ann
Anyone think there is any kind of hope for the investors if the deal goes through?
Ann
Theo:
What about the agreement/buyout between Nanobac & DNAP? Still going through? Is that a seperate issue and will it materialize? Any comments?
Ann
"These changes (nanotechnology) will generate large amounts of wealth and force wrenching changes in existing markets and institutions."
Ann